Pralsetinib Market by Indication: Non-Small Cell Lung Cancer, Thyroid Cancer, and More
The global pralsetinib market is driven by rising cancer incidence, particularly non-small cell lung cancer (NSCLC) and thyroid cancers, increasing demand for targeted therapies.